BACKGROUND: The purpose of this study was to examine patterns of failure and the relationship to radiation doses in patients with head and neck carcinoma of unknown primary (HNCUP). METHODS: We reviewed 85 patients with HNCUP treated with curative-intent radiation therapy (RT) during 1995 to 2012. RESULTS: There have been no failures in the pharyngeal axis. Relapse at initial neck sites of disease developed in 7 patients (8.2%). The median dose to these sites was 70 Gy (range, 63-70 Gy). Failure at neck sites without initial disease occurred in 4 patients (4.7%). The median dose was 54 Gy (range, 50-58.8 Gy). There were no contralateral failures in a small cohort of patients receiving unilateral treatment (n = 6). Percutaneous endoscopic gastrostomy (PEG) tube dependence at 12 months was 7.4%, and 2.5% at 3 years. Esophageal stricture developed in 5 patients (5.9%). CONCLUSION: RT for HNCUP produces excellent locoregional control rates with acceptably low levels of late toxicity. Doses prescribed to sites of eventual failure did not vary significantly from those sites that were treated and remain in control.
BACKGROUND: The purpose of this study was to examine patterns of failure and the relationship to radiation doses in patients with head and neck carcinoma of unknown primary (HNCUP). METHODS: We reviewed 85 patients with HNCUP treated with curative-intent radiation therapy (RT) during 1995 to 2012. RESULTS: There have been no failures in the pharyngeal axis. Relapse at initial neck sites of disease developed in 7 patients (8.2%). The median dose to these sites was 70 Gy (range, 63-70 Gy). Failure at neck sites without initial disease occurred in 4 patients (4.7%). The median dose was 54 Gy (range, 50-58.8 Gy). There were no contralateral failures in a small cohort of patients receiving unilateral treatment (n = 6). Percutaneous endoscopic gastrostomy (PEG) tube dependence at 12 months was 7.4%, and 2.5% at 3 years. Esophageal stricture developed in 5 patients (5.9%). CONCLUSION: RT for HNCUP produces excellent locoregional control rates with acceptably low levels of late toxicity. Doses prescribed to sites of eventual failure did not vary significantly from those sites that were treated and remain in control.
Authors: Hugo Villeneuve; Philippe Després; Bernard Fortin; Edith Filion; David Donath; Denis Soulières; Louis Guertin; Tarek Ayad; Apostolos Christopoulos; Phuc Felix Nguyen-Tan Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-15 Impact factor: 7.038
Authors: Stephanie M Perkins; Christopher R Spencer; Rebecca D Chernock; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; David I Kuperman; Wade L Thorstad Journal: Arch Otolaryngol Head Neck Surg Date: 2012-07
Authors: Lanea M Keller; Thomas J Galloway; Thomas Holdbrook; Karen Ruth; Donghua Yang; Cara Dubyk; Douglas Flieder; Miriam N Lango; Ranee Mehra; Barbara Burtness; John A Ridge Journal: Head Neck Date: 2014-01-13 Impact factor: 3.147
Authors: Paul B Romesser; Jonathan C Romanyshyn; Karen D Schupak; Jeremy Setton; Nadeem Riaz; Suzanne L Wolden; Daphna Y Gelblum; Eric J Sherman; Dennis Kraus; Nancy Y Lee Journal: Cancer Date: 2012-06-15 Impact factor: 6.860
Authors: Allen M Chen; Bao-Qing Li; D Gregory Farwell; Joseph Marsano; Srinivasan Vijayakumar; James A Purdy Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Debora Beldì; Barbara A Jereczek-Fossa; Alberto D'Onofrio; Giuseppina Gambaro; Maria Rosaria Fiore; Francesco Pia; Fausto Chiesa; Roberto Orecchia; Marco Krengli Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-22 Impact factor: 7.038
Authors: Lars Sivars; Anders Näsman; Nikolaos Tertipis; Andrea Vlastos; Torbjörn Ramqvist; Tina Dalianis; Eva Munck-Wikland; Sushma Nordemar Journal: Cancer Med Date: 2014-02-10 Impact factor: 4.452
Authors: Alexander D Sherry; Dario Pasalic; G Brandon Gunn; C David Fuller; Jack Phan; David I Rosenthal; William H Morrison; Erich M Sturgis; Neil D Gross; Maura L Gillison; Renata Ferrarotto; Adel K El-Naggar; Adam S Garden; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25